Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 329-334

  Labarga, Pablo ^a,b   Fernandez Montero, Jose ^a   De Mendoza, Carmen ^c   Barreiro, Pablo ^a   Pinilla, Javier ^d   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Clinica La Luz   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL SAN PEDRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; VIRUS REPLICATION; COMPLICATION; HEPATITIS C, CHRONIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84937557719     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2909     Document Type: Article

References (33)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19:850-858.
2. Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014; 105:1-7.
3. de Lédinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008; 15:427-433.
4. Macías J, Márquez M, Téllez F, et al. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis 2013; 57:1401-1408.
5. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Smith C, Sabin CA, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24:1537-1548.
6. Wada N, Jacobson L, Cohen M. Cause-specific life expectancies after 3.5 years of age for HIV-infected and HIV-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-125.
7. Rockstroh JK, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol 2013; 59:213-220.
8. Soriano V, Vispo E, de Mendoza C, et al. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. Antivir Ther 2013; 18:1033-1035.
9. Hara K, Rivera M, Koh C, et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 2014; 209:38-45.
10. Barreiro P, Vispo E, Maida I, et al. Very late HCV relapse following triple therapy for hepatitis C. Antivir Ther 2014; 19:723-724.
11. Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399-403.
12. Manne V, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol 2014; 48:e76-e84.
13. Morgan TR, Ghany M, Kim H, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-844.
14. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900.
15. Soriano V, Labarga P, Ruiz-Sancho A, Garcia-Samaniego J, Barreiro P. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006; 20:2225-2227.
16. Berenguer J, Alvarez-Pellicer J, Martin P, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality inpatients coinfected with HIV and hepatitis C virus. Hepatology 2009; 50:407-413.
17. Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56:1646-1653.
18. Labarga P, Fernandez-Montero JV, Barreiro P, et al. Changes in liver fibrosis in HIV-HCV coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat 2014; 21:475-479.
19. Limketkai BN, Mehta S, Sutcliffe C, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-378.
20. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59:1692-1705.
21. Hagan LM, Sulkowski M, Schinazi R. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60:37-45.
22. Reau NS, Jensen D. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 2014; 59:1246-1249.
23. Thompson MA, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 1 July 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
25. European AIDS Clinical Society (EACS). Guidelines version 7.1 (October 2013). (Accessed 1 July 2014.) Available from www.eacsociety.org/guidelines/eacs-guidelines/eacsguidelines.html
26. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
27. Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, et al. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014; 28:1379-1391.
28. Fernández-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis 2014; 58:1549-1553.
29. Bräu N, Salvatore M, Ríos-Bedoya C, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
30. Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014; 60:823-831.
31. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-16.
32. Lo Re V, Kallan M, Tate J, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160:369-379.
33. Konerman MA, Mehta S, Sutcliffe C, et al. Fibrosis progression in HIV/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59:767-775.